Is Retinoic acid (tretinoin) safe for babies and kids?

Retinoic acid is contraindicated absolutely during pregnancy — it is one of the most potent human teratogens known. FDA Pregnancy Category X (confirmed human teratogen, risks clearly outweigh any possible benefit) applies to all retinoids. Retinoid embryopathy following use of topical tretinoin during the first trimester of pregnancy is well-documented in the literature; characteristic malformations include craniofacial defects (microtia, cleft palate, microcephaly), cardiac defects (transposition of great arteries, tetralogy of Fallot), thymic aplasia or hypoplasia, CNS malformations (cerebellar hypoplasia, hydrocephalus), and limb defects. The critical exposure window is the period of organogenesis (approximately gestational weeks 3–10). The teratogenic mechanism involves disruption of the precisely regulated spatiotemporal gradients of retinoic acid signaling that govern Hox gene expression patterns during embryonic development — exogenous retinoic acid overwhelms the homeostatic mechanisms that normally maintain precise gradients of retinoic acid concentration in different embryonic compartments. Systemic retinoids (isotretinoin, acitretin) carry extreme teratogenicity risk and require mandated iPLEDGE program enrollment in the US, including two forms of contraception and monthly pregnancy testing. For topical tretinoin, systemic absorption is much lower, but the absolute prohibition during pregnancy is maintained by FDA because the margin of safety for teratogenicity is unknown and animal data demonstrate teratogenicity via topical route at high doses. All women of childbearing age using tretinoin must use effective contraception.

Retinoic acid is contraindicated absolutely during pregnancy — it is one of the most potent human teratogens known. FDA Pregnancy Category X (confirmed human teratogen, risks clearly outweigh any possible benefit) applies to all retinoids. Retinoid embryopathy following use of topical tretinoin during the first trimester of pregnancy is well-documented in the literature; characteristic malformations include craniofacial defects (microtia, cleft palate, microcephaly), cardiac defects (transposition of great arteries, tetralogy of Fallot), thymic aplasia or hypoplasia, CNS malformations (cerebellar hypoplasia, hydrocephalus), and limb defects. The critical exposure window is the period of organogenesis (approximately gestational weeks 3–10). The teratogenic mechanism involves disruption of the precisely regulated spatiotemporal gradients of retinoic acid signaling that govern Hox gene expression patterns during embryonic development — exogenous retinoic acid overwhelms the homeostatic mechanisms that normally maintain precise gradients of retinoic acid concentration in different embryonic compartments. Systemic retinoids (isotretinoin, acitretin) carry extreme teratogenicity risk and require mandated iPLEDGE program enrollment in the US, including two forms of contraception and monthly pregnancy testing. For topical tretinoin, systemic absorption is much lower, but the absolute prohibition during pregnancy is maintained by FDA because the margin of safety for teratogenicity is unknown and animal data demonstrate teratogenicity via topical route at high doses. All women of childbearing age using tretinoin must use effective contraception.